"It will be another virusa mutated virus or another [type of] virus, or something like thatbut these comorbidities are going to be the same." But one question that remains is whether Semaglutide or the general decline in weight in the population that it might bring about could limit the spread of a new virus
Inaccuracy in subgroup classification might dilute the observed magnitude of effect modification
Notably, the SELECT trial demonstrated a 20% reduction in risks of heart attack, stroke, and death from cardiovascular disease with over three years of semaglutide use, highlighting the sustained effects of these drugs
Body aches often accompany the first injection and again at each dose increase, as the body re-adapts to higher receptor activation
That observation ultimately reshaped the trajectory of the entire drug class, leading to obesity-specific formulations and, more recently, FDA approvals for additional chronic conditions